PL363168A1 - Cyklopentanole, kompozycje zawierające takie związki i sposoby leczenia - Google Patents

Cyklopentanole, kompozycje zawierające takie związki i sposoby leczenia

Info

Publication number
PL363168A1
PL363168A1 PL01363168A PL36316801A PL363168A1 PL 363168 A1 PL363168 A1 PL 363168A1 PL 01363168 A PL01363168 A PL 01363168A PL 36316801 A PL36316801 A PL 36316801A PL 363168 A1 PL363168 A1 PL 363168A1
Authority
PL
Poland
Prior art keywords
treatment
cyclopentanoindoles
compounds
methods
compositions containing
Prior art date
Application number
PL01363168A
Other languages
English (en)
Other versions
PL207342B1 (pl
Inventor
Marc Labelle
Claudio Sturino
Bruno Roy
Carl Berthelette
Michael Boyd
Nicolas Lachance
John Scheigetz
Original Assignee
Merck Frosst Canada & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada & Co. filed Critical Merck Frosst Canada & Co.
Publication of PL363168A1 publication Critical patent/PL363168A1/pl
Publication of PL207342B1 publication Critical patent/PL207342B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/38—TPC being performed in particular situations
    • H04W52/46—TPC being performed in particular situations in multi hop networks, e.g. wireless relay networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B17/00—Monitoring; Testing
    • H04B17/30—Monitoring; Testing of propagation channels
    • H04B17/309—Measuring or estimating channel quality parameters
    • H04B17/318—Received signal strength
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W48/00—Access restriction; Network selection; Access point selection
    • H04W48/02—Access restriction performed under specific conditions
    • H04W48/04—Access restriction performed under specific conditions based on user or terminal location or mobility data, e.g. moving direction, speed
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/06—TPC algorithms
    • H04W52/14—Separate analysis of uplink or downlink
    • H04W52/146—Uplink power control
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/28—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non transmission
    • H04W52/288—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non transmission taking into account the usage mode, e.g. hands-free, data transmission, telephone
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W48/00—Access restriction; Network selection; Access point selection
    • H04W48/20—Selecting an access point
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H04W52/245—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters taking into account received signal strength
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H04W52/247—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters where the output power of a terminal is based on a path parameter sent by another terminal
PL363168A 2000-07-25 2001-07-23 Cyklopentanoindol i zawierająca go kompozycja farmaceutyczna PL207342B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22068300P 2000-07-25 2000-07-25
PCT/CA2001/001069 WO2002008186A2 (en) 2000-07-25 2001-07-23 Cyclopentanoindoles, compositions containing such compounds and methods of treatment

Publications (2)

Publication Number Publication Date
PL363168A1 true PL363168A1 (pl) 2004-11-15
PL207342B1 PL207342B1 (pl) 2010-12-31

Family

ID=22824535

Family Applications (1)

Application Number Title Priority Date Filing Date
PL363168A PL207342B1 (pl) 2000-07-25 2001-07-23 Cyklopentanoindol i zawierająca go kompozycja farmaceutyczna

Country Status (34)

Country Link
US (1) US6410583B1 (pl)
EP (1) EP1305286B1 (pl)
JP (1) JP4119745B2 (pl)
KR (1) KR100746814B1 (pl)
CN (1) CN1214007C (pl)
AT (1) ATE284388T1 (pl)
AU (2) AU7743001A (pl)
BG (1) BG66084B1 (pl)
BR (1) BR0112756A (pl)
CA (1) CA2416867C (pl)
CZ (1) CZ2003236A3 (pl)
DE (1) DE60107687T2 (pl)
DK (1) DK1305286T3 (pl)
DZ (1) DZ3402A1 (pl)
EA (1) EA006765B1 (pl)
EC (1) ECSP034428A (pl)
EE (1) EE05287B1 (pl)
ES (1) ES2231526T3 (pl)
GE (1) GEP20053595B (pl)
HK (1) HK1058934A1 (pl)
HR (1) HRP20021039B1 (pl)
HU (1) HUP0301745A3 (pl)
IL (2) IL153406A0 (pl)
IS (1) IS2170B (pl)
MX (1) MXPA03000710A (pl)
NO (1) NO325011B1 (pl)
NZ (1) NZ523106A (pl)
PL (1) PL207342B1 (pl)
PT (1) PT1305286E (pl)
RS (1) RS50491B (pl)
SK (1) SK287507B6 (pl)
UA (1) UA73787C2 (pl)
WO (1) WO2002008186A2 (pl)
ZA (1) ZA200300554B (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217725B2 (en) * 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
US7273883B2 (en) * 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
AR031202A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
AR031199A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
ES2230382T3 (es) * 2000-11-03 2005-05-01 Wyeth Ciclopental(b)(1,4)diazpino(6,7,1-hi)indoles como antagonistas de 5ht2c.
AR031196A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de ciclopenta (b) (1,4)-diazepino (6,7,1-hi) indoles y derivados
AR031200A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
AR031195A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta (b) (1,4) diazepino (6,7,1) diazepino (6,7,1-hi) indol
US7141563B2 (en) 2000-11-03 2006-11-28 Wyeth Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi] indole derivatives
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
TW200400818A (en) 2002-05-21 2004-01-16 Wyeth Corp Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
CA2526013A1 (en) * 2003-05-20 2004-12-02 Merck Frosst Canada Ltd. Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists
EP1638967A2 (en) * 2003-06-12 2006-03-29 Merck Frosst Canada Ltd. Cycloalkanepyrrolopyridines as dp receptor antagonists
ATE464048T1 (de) * 2003-08-07 2010-04-15 Merck Sharp & Dohme Behandlung von alzheimer-krankheit und verwandten zuständen
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
WO2006008118A1 (en) 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CA2603757A1 (en) * 2005-04-13 2006-10-26 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
US7902177B2 (en) 2005-05-02 2011-03-08 Wandzel Richard A Treatment of congestion using steroids and adrenergics
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
WO2008097535A2 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
HUE030424T2 (en) * 2008-07-23 2017-05-29 Arena Pharm Inc Substituted 1,2,3,4-tetrahydrocyclopenta [b] indol-3-ylacetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
SI2342205T1 (sl) 2008-08-27 2016-09-30 Arena Pharmaceuticals, Inc. Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj
WO2010030360A1 (en) 2008-09-11 2010-03-18 Arena Pharmaceuticals, Inc. 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
EP2346866B1 (en) 2008-09-25 2013-11-27 Merck Canada Inc. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
EP2379080A1 (en) 2009-01-13 2011-10-26 ProteoSys AG Pirenzepine as otoprotective agent
JP2013508339A (ja) 2009-10-26 2013-03-07 バイエル・クロップサイエンス・アーゲー ４−［［（６−クロロピリジン−３−イル）メチル］（２，２−ジフルオロエチル）アミノ］フラン−２（５ｈ）−オンの新規固体形態
ES2937386T3 (es) 2010-01-27 2023-03-28 Arena Pharm Inc Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo
WO2011109471A1 (en) 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
US9797903B2 (en) 2012-10-24 2017-10-24 Winthrop-University Hospital Non-invasive biomarker to identify subject at risk of preterm delivery
EP3242666A1 (en) 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
WO2016128565A1 (en) * 2015-02-13 2016-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
AU2018331400A1 (en) 2017-09-13 2020-04-02 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
US11279656B2 (en) * 2017-10-27 2022-03-22 Applied Materials, Inc. Nanopowders, nanoceramic materials and methods of making and use thereof
WO2020051378A1 (en) 2018-09-06 2020-03-12 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN115260173A (zh) * 2021-04-30 2022-11-01 厦门宝太生物科技股份有限公司 环戊烷并吲哚类支链酸衍生物及其制备方法和应用
CN116854622A (zh) * 2023-07-10 2023-10-10 青岛科技大学 一种多取代的2,4-二氢环戊二烯并[b]吲哚类化合物的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
ATE61047T1 (de) 1986-01-23 1991-03-15 Merck Frosst Canada Inc Tetrahydrocarbazol-1-alkansaeuren.
US5221678A (en) 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
GB9101375D0 (en) 1991-01-22 1991-03-06 Erba Carlo Spa N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
KR100428601B1 (ko) * 1995-06-21 2004-09-16 시오노기세이야쿠가부시키가이샤 비사이클릭아미노유도체및이들을함유하는프로스타글란딘디2길항제
PL191760B1 (pl) * 1996-12-13 2006-06-30 Shionogi & Co Związki, pochodne benzotiofenokarboksyamidu, związki pośrednie, kompozycja farmaceutyczna zawierająca te pochodne oraz lek do leczenia blokady nosa
DE69925270T2 (de) * 1998-06-03 2006-02-23 Shionogi & Co., Ltd. Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten

Also Published As

Publication number Publication date
DE60107687D1 (de) 2005-01-13
IL153406A (en) 2008-03-20
HUP0301745A2 (hu) 2003-09-29
EE05287B1 (et) 2010-04-15
YU97902A (sh) 2006-05-25
ECSP034428A (es) 2003-03-10
CA2416867A1 (en) 2002-01-31
JP4119745B2 (ja) 2008-07-16
DE60107687T2 (de) 2005-12-01
AU7743001A (en) 2002-02-05
GEP20053595B (en) 2005-08-10
JP2004504380A (ja) 2004-02-12
CA2416867C (en) 2008-03-25
HK1058934A1 (en) 2004-06-11
HRP20021039B1 (en) 2011-03-31
EA200300171A1 (ru) 2003-06-26
EE200300033A (et) 2004-10-15
ATE284388T1 (de) 2004-12-15
CN1443165A (zh) 2003-09-17
RS50491B (sr) 2010-03-02
NZ523106A (en) 2005-01-28
WO2002008186A2 (en) 2002-01-31
KR20030024810A (ko) 2003-03-26
NO325011B1 (no) 2008-01-14
UA73787C2 (en) 2005-09-15
ES2231526T3 (es) 2005-05-16
IL153406A0 (en) 2003-07-06
US6410583B1 (en) 2002-06-25
PL207342B1 (pl) 2010-12-31
DZ3402A1 (fr) 2002-01-31
EP1305286A2 (en) 2003-05-02
HRP20021039A2 (en) 2004-10-31
NO20030374L (no) 2003-01-24
PT1305286E (pt) 2005-04-29
EP1305286B1 (en) 2004-12-08
IS6655A (is) 2002-12-12
EA006765B1 (ru) 2006-04-28
BG66084B1 (bg) 2011-03-31
DK1305286T3 (da) 2005-03-14
NO20030374D0 (no) 2003-01-24
BR0112756A (pt) 2003-06-24
HUP0301745A3 (en) 2010-03-29
AU2001277430B2 (en) 2006-05-25
ZA200300554B (en) 2004-04-23
CN1214007C (zh) 2005-08-10
SK287507B6 (sk) 2010-12-07
BG107438A (bg) 2003-09-30
CZ2003236A3 (cs) 2003-05-14
SK932003A3 (en) 2003-06-03
KR100746814B1 (ko) 2007-08-06
WO2002008186A3 (en) 2002-03-21
IS2170B (is) 2006-11-15
MXPA03000710A (es) 2003-06-04

Similar Documents

Publication Publication Date Title
IL153406A0 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
MY137040A (en) Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
AU3652102A (en) Compounds and their uses
AU2002239344A1 (en) Pyrazolopyridines
TW200510407A (en) Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors
DE60112330D1 (en) Pyrazolopyridinderivate
MXPA06003363A (es) Derivados de fenil-piperazina como moduladores de receptores muscarinicos.
PL371127A1 (pl) Pochodne 6-amino-morfinianu, metody ich otrzymywania oraz ich zastosowania
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
MY128241A (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
MXPA03010766A (es) Nuevos compuestos y composiciones como inhibicores de las catepsinas.
WO2002024695A3 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
WO2004111047A3 (en) Cycloalkanepyrrolopyridines as dp receptor antagonists
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
MXPA03005374A (es) Carbazoles antitumorales.
YU26001A (sh) Derivati ureidopiperidina kao selektivni antagonisti ljudskih nk3 receptora
MXPA03005400A (es) Metodo para preparacion de 11 (12)-pentadecen-15-olidos.
AU2001287673A1 (en) Novel trioxepan compounds
SG143979A1 (en) Novel compounds and compositions as cathepsin inhibitors

Legal Events

Date Code Title Description
VDSO Invalidation of derivated patent or utility model

Ref document number: 386657

Country of ref document: PL

Kind code of ref document: A1